Sana Biotechnology (SANA) Stock: Buy, Sell, or Hold?
SANA - Sana Biotechnology, Inc. Common Stock
$2.41
-0.21 (-8.02%)
▼
5d:
-12.36%
30d:
-24.69%
90d:
-32.11%
WAIT
LOW Confidence
Analysis Updated: Oct 13, 2026 12:00 AM ET
Earnings: Nov 05, 2026
21d
Get Alerted When SANA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: SANA is down 12.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: SANA is down 12.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: SANA is currently trading at $2.41, which is considered oversold relative to its 30-day fair value range of $2.73 to $3.27.
Technical Outlook: Technically, SANA is in a uptrend. The price is currently testing key support at $2.37. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.0% recently.
Market Sentiment: SANA scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.43 (+249.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SANA is in a uptrend. The price is currently testing key support at $2.37. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.0% recently.
Market Sentiment: SANA scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.43 (+249.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.73 -
$3.27
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.0%)
- BULLISH: Trading 249.7% below Wall St target ($8.43)
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.73 -
$3.27
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.37
Resistance Level
$3.05
Current Trend
Uptrend
Technical data as of
Oct 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.34
Wall Street Target
$8.43
(+249.7%)
Share & Embed Analysis
Last updated: October 14, 2026 12:02 AM ET
Data refreshes hourly during market hours. Next update: 1:02 AM
Data refreshes hourly during market hours. Next update: 1:02 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SANA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
27 analysts |
$92 | 59 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
22 analysts |
$109 | 56 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
17 analysts |
$37 | 64 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$285 | 44 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 72 BUY |
